JP2019514979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514979A5 JP2019514979A5 JP2018558293A JP2018558293A JP2019514979A5 JP 2019514979 A5 JP2019514979 A5 JP 2019514979A5 JP 2018558293 A JP2018558293 A JP 2018558293A JP 2018558293 A JP2018558293 A JP 2018558293A JP 2019514979 A5 JP2019514979 A5 JP 2019514979A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- lipid
- pharmaceutical composition
- rofleponide
- purine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims 23
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 19
- 230000003110 anti-inflammatory effect Effects 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical group C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims 11
- 229950004432 rofleponide Drugs 0.000 claims 11
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 6
- 229960004436 budesonide Drugs 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- 102000014702 Haptoglobin Human genes 0.000 claims 2
- 108050005077 Haptoglobin Proteins 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 229940049918 linoleate Drugs 0.000 claims 2
- 229940105132 myristate Drugs 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212753A JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333574P | 2016-05-09 | 2016-05-09 | |
| US62/333,574 | 2016-05-09 | ||
| US201662359429P | 2016-07-07 | 2016-07-07 | |
| US62/359,429 | 2016-07-07 | ||
| US201762449623P | 2017-01-24 | 2017-01-24 | |
| US62/449,623 | 2017-01-24 | ||
| PCT/EP2017/060891 WO2017194454A1 (en) | 2016-05-09 | 2017-05-08 | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212753A Division JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514979A JP2019514979A (ja) | 2019-06-06 |
| JP2019514979A5 true JP2019514979A5 (enExample) | 2020-06-18 |
| JP7066632B2 JP7066632B2 (ja) | 2022-05-13 |
Family
ID=58671696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558293A Active JP7066632B2 (ja) | 2016-05-09 | 2017-05-08 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
| JP2021212753A Withdrawn JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212753A Withdrawn JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11458106B2 (enExample) |
| EP (1) | EP3454835B1 (enExample) |
| JP (2) | JP7066632B2 (enExample) |
| CN (1) | CN109152735B (enExample) |
| ES (1) | ES2871537T3 (enExample) |
| WO (1) | WO2017194454A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3766916T (lt) | 2014-06-25 | 2023-01-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| EP4420679A3 (en) | 2015-06-29 | 2024-12-04 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| PL3368507T3 (pl) | 2015-10-28 | 2023-03-27 | Acuitas Therapeutics Inc. | Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych |
| WO2018081480A1 (en) * | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| JP7066632B2 (ja) | 2016-05-09 | 2022-05-13 | アストラゼネカ・アクチエボラーグ | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| AU2018256877B2 (en) | 2017-04-28 | 2022-06-02 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CA3113449A1 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| EP3908568B1 (en) | 2019-01-11 | 2024-06-26 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| US20220226243A1 (en) * | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| AU2021211894A1 (en) * | 2020-01-21 | 2022-09-01 | Etherna Immunotherapies Nv | Lipid nanoparticles |
| IL299787A (en) | 2020-07-16 | 2023-03-01 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| JP2024542112A (ja) * | 2021-11-05 | 2024-11-13 | ジー２ジーバイオ インコーポレイテッド | 非経口併用投与用薬学的キット |
| CN118647600A (zh) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
| WO2023148303A1 (de) * | 2022-02-02 | 2023-08-10 | Mslsolutions Gmbh | Verfahren zur medikament- und impfstoffherstellung |
| CN114617980A (zh) * | 2022-03-09 | 2022-06-14 | 广州国家实验室 | 可电离脂质纳米颗粒及其应用 |
| WO2024148428A1 (en) * | 2023-01-09 | 2024-07-18 | Northmirs, Inc. | Microrna-based particle for the treatment of dysregulated immune response |
| WO2025215636A1 (en) | 2024-04-08 | 2025-10-16 | Yeda Research And Development Co. Ltd. | Anti-defense system polypeptides and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| US20060062841A1 (en) | 2004-09-01 | 2006-03-23 | Leaf Huang | Liposomal vectors |
| CN101708338B (zh) | 2008-12-26 | 2014-06-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 含甾体结构的前药及其高度分散制剂 |
| SG10201912450XA (en) * | 2009-06-10 | 2020-03-30 | Arbutus Biopharma Corp | Improved lipid formulation |
| CN104651408A (zh) | 2009-06-15 | 2015-05-27 | 阿尔尼拉姆医药品有限公司 | 靶向pcsk9基因的脂质配制的dsrna |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| KR20140031227A (ko) | 2011-03-24 | 2014-03-12 | 레오 파마 에이/에스 | 지질 나노입자들 및 코르티코스테로이드 또는 비타민 ｄ 유도체를 포함하는 조성물 |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| MX2021005697A (es) | 2013-05-03 | 2021-07-07 | Selecta Biosciences Inc | Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria. |
| LT3766916T (lt) | 2014-06-25 | 2023-01-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| JP7066632B2 (ja) | 2016-05-09 | 2022-05-13 | アストラゼネカ・アクチエボラーグ | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
-
2017
- 2017-05-08 JP JP2018558293A patent/JP7066632B2/ja active Active
- 2017-05-08 WO PCT/EP2017/060891 patent/WO2017194454A1/en not_active Ceased
- 2017-05-08 US US15/589,181 patent/US11458106B2/en active Active
- 2017-05-08 ES ES17721707T patent/ES2871537T3/es active Active
- 2017-05-08 CN CN201780026989.5A patent/CN109152735B/zh active Active
- 2017-05-08 EP EP17721707.2A patent/EP3454835B1/en active Active
-
2021
- 2021-12-27 JP JP2021212753A patent/JP2022058438A/ja not_active Withdrawn
-
2022
- 2022-08-02 US US17/879,362 patent/US20220370370A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514979A5 (enExample) | ||
| US20220370370A1 (en) | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | |
| JP7275111B2 (ja) | 脂質ナノ粒子の生成方法 | |
| Zadeh Mehrizi et al. | Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus | |
| EP3448393A1 (en) | Novel complexes of immunostimulatory compounds, and uses thereof | |
| JP2015515992A5 (enExample) | ||
| Ryan | Nanobiotechnology applications of reconstituted high density lipoprotein | |
| JP2012067116A5 (enExample) | ||
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| JP2017509690A5 (enExample) | ||
| Hong et al. | Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus | |
| Li et al. | The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid | |
| WO2017092230A1 (zh) | 双黄酮化合物及其治疗癌症和制备药物的用途 | |
| JP2006508912A5 (enExample) | ||
| CN102429897B (zh) | 一种提高桑色素口服生物利用度的药物组合物 | |
| Chellappan et al. | Vesicular systems containing curcumin and their applications in respiratory disorders–a mini review | |
| Liu et al. | Targeted delivery of macrophage membrane biomimetic liposomes through intranasal administration for treatment of ischemic stroke | |
| JP2023526707A (ja) | カバジタキセル弱塩基性誘導体およびその製剤 | |
| CN117205319B (zh) | Hc030031在制备预防或治疗百草枯中毒引起的肺损伤的药物中的应用 | |
| CN101805285A (zh) | 含烟酸姜黄素酯衍生物及其制造方法和用途 | |
| WO2016008289A1 (zh) | 一种盐酸伊立替康纳米脂束制剂及其制备方法 | |
| CN106133024B (zh) | 用于疏水性药物递送的新颖的基于聚合物的助水溶物 | |
| CN119654308A (zh) | 可离子化脂质及包含其的纳米颗粒 | |
| Wang et al. | The intervention effects of different drugs on dendritic cells in acute pancreatitis in mouse | |
| Thompson et al. | Pharmacokinetics of TD-8236, a Lung-Selective pan-JAK Inhibitor, Following Single-Dose Administration in Mice, Rats, and Dogs |